Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | ESR1 | P03372 | 4/20 | 0.33 |
| ▸ | ESR2 | Q92731 | 4/20 | 0.33 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.31 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.31 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.31 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.31 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.31 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.31 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 2/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1582585 | 0.90 | CYP3A4 (0.39) | CYP3A4TDP1CHRNB2CHRNB4CHRNA3 | |
| SCHEMBL301089 | 0.90 | CYP3A4 (0.39) | CYP3A4TDP1ESR1ESR2CHRNB2 | |
| SCHEMBL15047274 | 0.90 | CYP3A4 (0.39) | CYP3A4TDP1ESR1ESR2POLB | |
| SCHEMBL1582759 | 0.89 | ACHE (0.37) | CYP3A4TDP1ESR2SIGMAR1GAA | |
| SCHEMBL13456274 | 0.87 | CYP3A4 (0.38) | CYP3A4TDP1CHRNB2CHRNB4CHRNA3 | |
| SCHEMBL20899224 | 0.87 | CYP3A4 (0.38) | CYP3A4TDP1CHRNB2CHRNB4CHRNA3 | |
| SCHEMBL301069 | 0.87 | CYP3A4 (0.38) | CYP3A4TDP1CHRNB2CHRNB4CHRNA3 | |
| SCHEMBL301035 | 0.87 | CYP3A4 (0.38) | CYP3A4TDP1CHRNB2CHRNB4CHRNA3 | |
| SCHEMBL34871 | 0.87 | CYP3A4 (0.38) | CYP3A4TDP1CHRNB2CHRNB4CHRNA3 | |
| Lithium SCHEMBL30167974 | 0.87 | CYP3A4 (0.38) | CYP3A4TDP1CHRNB2CHRNB4CHRNA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2610248-B1 | METHOD FOR PRODUCING PHENYL-SUBSTITUTED HETEROCYCLIC DERIVATIVE BY MEANS OF COUPLING METHOD USING A PALLADIUM COMPOUND | TEIJIN PHARMA LTD (JP) | 2016-06-08 | — | — | EP | disclosed |
| CN-103068807-B | By using the preparation method of phenyl substituted heterocycle derivative of coupling process of palladium compound | TEIJIN PHARMA LTD. (JP) | 2016-05-25 | — | — | CN | disclosed |
| US-8952174-B2 | Process for producing phenyl-substituted heterocyclic derivative through coupling using transition metal catalyst | TEIJIN PHARMA LIMITED (JP) | 2015-02-10 | — | — | US | disclosed |
| CN-102333765-B | Process for producing phenyl-substituted heterocyclic derivative through coupling using transition metal catalyst | TEIJIN PHARMA LTD | 2015-01-14 | — | — | CN | disclosed |
| US-8916714-B2 | Method for producing phenyl-substituted heterocyclic derivative by means of coupling method using palladium compound | TEIJIN PHARMA LIMITED (JP) | 2014-12-23 | — | — | US | disclosed |
| EP-2610248-A1 | METHOD FOR PRODUCING PHENYL-SUBSTITUTED HETEROCYCLIC DERIVATIVE BY MEANS OF COUPLING METHOD USING A PALLADIUM COMPOUND | Teijin Pharma Limited (JP) | 2013-07-03 | — | — | EP | disclosed |
| US-20130158272-A1 | METHOD FOR PRODUCING PHENYL-SUBSTITUTED HETEROCYCLIC DERIVATIVE BY MEANS OF COUPLING METHOD USING PALLADIUM COMPOUND | TEIJIN PHARMA LIMITED (JP) | 2013-06-20 | — | — | US | disclosed |
| CN-103068807-A | Method for producing phenyl-substituted heterocyclic derivative by means of coupling method using a palladium compound | TEIJIN PHARMA LTD | 2013-04-24 | — | — | CN | disclosed |
| CN-102333765-A | Process for producing phenyl-substituted heterocyclic derivative through coupling using transition metal catalyst | TEIJIN PHARMA LTD | 2012-01-25 | — | — | CN | disclosed |
| EP-2404908-A1 | PROCESS FOR PRODUCING PHENYL-SUBSTITUTED HETEROCYCLIC DERIVATIVE THROUGH COUPLING USING TRANSITION METAL CATALYST | Teijin Pharma Limited (JP) | 2012-01-11 | — | — | EP | disclosed |
| US-20110313169-A1 | PROCESS FOR PRODUCING PHENYL-SUBSTITUTED HETEROCYCLIC DERIVATIVE THROUGH COUPLING USING TRANSITION METAL CATALYST | TEIJIN PHARMA LIMITED (JP) | 2011-12-22 | — | — | US | disclosed |
| EP-2298926-A1 | Adeno-associated virus (AAV) clades, sequences, vectors containing same, and uses thereof | The Trustees of The University of Pennsylvania (US) | 2011-03-23 | — | — | EP | disclosed |
| EP-2292780-A2 | Adeno-associated virus (AAV) clades, sequences, vectors containing same, and uses thereof | The Trustees of the University of Pennsylvania (US) | 2011-03-09 | — | — | EP | disclosed |
| US-7736654-B2 | Nucleic acids and corresponding proteins useful in the detection and treatment of various cancers | AGENSYS, INC. (US) | 2010-06-15 | — | — | US | disclosed |
| EP-0927577-B1 | Ruthenium metathesis catalyst and method for olefin metathesis using the same | TAKASAGO PERFUMERY CO LTD (JP) | 2004-06-23 | — | — | EP | disclosed |
| US-6313365-B1 | Ruthenium metathesis catalyst and method for producing olefin reaction product by metathesis reaction using the same | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2001-11-06 | — | — | US | disclosed |
| US-6175047-B1 | A CATALYST MIXTURE INCLUDING A RUTHENIUM COMPOUND, A DIHALOGENO COMPOUND, A TERMINAL ALKYNE; AS A CATALYST FOR A CARBON-CARBON BOND FORMATION REACTION | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2001-01-16 | — | — | US | disclosed |
| EP-0927577-A1 | Ruthenium metathesis catalyst and method for producing olefin reaction product by metathesis reaction using the same | Takasago International Corporation (JP) | 1999-07-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110313169-A1 | PROCESS FOR PRODUCING PHENYL-SUBSTITUTED HETEROCYCLIC DERIVATIVE THROUGH COUPLING USING TRANSITION METAL CATALYST | XDH, PAH, HPRT1 | CYP3A4 47/4885TDP1 1180/4885ESR1 3942/4885 |
| US-20130158272-A1 | METHOD FOR PRODUCING PHENYL-SUBSTITUTED HETEROCYCLIC DERIVATIVE BY MEANS OF COUPLING METHOD USING PALLADIUM COMPOUND | XDH, AOC1, PAH | CYP3A4 325/4885TDP1 1332/4885ESR1 4102/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.